Navigation Links
Protox Announces Positive Clinical Data from Prostate Cancer Study

VANCOUVER, British Columbia, July 10, 2007 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today announced positive top-line results from its Phase 1 clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancer following radiation failure. The trial results indicate that PRX302 is safe and well tolerated and shows promising signs of therapeutic activity following a single intra-prostatic treatment.

"The completion of the PRX302 Phase 1 trial is encouraging from two perspectives," said Dr. Scott Coffield, Principal Investigator from the lead site, Scott and White Memorial Hospital. "First, there was therapeutic benefit demonstrated through overall PSA reduction in study patients, as well as a reduction in the number of positive biopsies after treatment. Second, there was no significant adverse side effect profile at the highest dose of PRX302 given to patients in this trial."

"It is heartening to see promising results at this stage of the clinical development program in a patient population which has limited therapeutic options," said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. "These data support our heightened confidence regarding the potential of PRX302 for the treatment of not only prostate cancer, but also BPH, which is currently being evaluated in an ongoing Phase I trial."

This study is intended to examine the safety, tolerability and therapeutic activity of PRX302 in patients with localized recurrent prostate cancer who show signs of disease progression as evidenced by rising levels of PSA (prostate specific antigen) following radiation treatment. Using a well-established, image-guided technique, PRX302 was administered directly into the prostate. A total of 24 patients were treated in this trial. Protox has concluded that despite a 100-fold escalation in dose, the maximum tolerated dose (MTD) was not reached in this study while e
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/22/2014)... 2014  Sprout Pharmaceuticals today announced positive preliminary results from ... with flibanserin up to 200 mg at bedtime had no ... the 20 th Annual Fall Scientific Meeting of the ... in Miami . The Phase ... Response Letter and the Formal Dispute Resolution that was filed ...
(Date:11/22/2014)... 2014  New data demonstrates that flibanserin, a novel, ... of female sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), ... in premenopausal women when taken at bedtime. The data ... North America,s (SMSNA) 20th Annual Fall ... SMSNA accepted this study as a late ...
(Date:11/22/2014)... MONMOUTH JUNCTION, N.J. , Nov. 21, 2014 ... immunotherapy company commercializing its European Union approved CytoSorb® ... countries worldwide, was awarded the Beacon of Light ... Annual Awards Celebration.  Dr. ... stated, "It is an honor to be recognized ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... Mass., Sept. 16 Echo Therapeutics, Inc. (OTC ... developing its needle-free Symphony™ tCGM System as a ... its Prelude™ SkinPrep System for transdermal drug delivery, ... and Chief Executive Officer, will present at the ...
... Ascendant Neuro is pleased to announce the addition of ... who has joined to further the advancement of the ... innovative use of neurostimulators . Dr. Alo will serve ... Dr. Alo graduated from Texas A&M University College ...
Cached Medicine Technology:Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference 2Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference 3Kenneth Alo, M.D., Joins Ascendant Neuro as Director of Neuromodulation and Clinical Research 2Kenneth Alo, M.D., Joins Ascendant Neuro as Director of Neuromodulation and Clinical Research 3
(Date:11/23/2014)... Tbdress.com has recently announced that its Special Friday Shoes ... special offer will provide ladies many gorgeous shoes at greatly ... largest women’s dresses retailers, and its shoes include many models ... on that day: Everything at Tbdress.com is up to 90% ... , People can use the following coupon codes as well: ...
(Date:11/23/2014)... BC (PRWEB) November 23, 2014 Pro Ace ... announced that it will now be providing an 8 year ... of hot water tank installations went up due to the ... to assure its customers of the premium service that the ... offering 8 year warranty on John Wood and Bradford hot ...
(Date:11/23/2014)... New York, NY (PRWEB) November 23, 2014 ... ) that allege heart attacks, strokes, deep vein ... been filed in a federal multidistrict litigation (MDL) ... Liebhard LLP reports. , Court documents updated ... on Multidistrict Litigation (JPML) show the filing of ...
(Date:11/23/2014)... Close friends have more influence on teens, alcohol use ... says. "We,ve known for a long time ... alcohol use, but there are no common studies that ... group,s influence on those decisions," Jonathon Beckmeyer, an assistant ... in a university news release. Beckmeyer analyzed data ...
(Date:11/23/2014)... holidays can be a challenge for families of children ... an expert says. "Holidays with family can be ... have children with special needs, some care must be ... of the Sciences in Philadelphia, said in a university ... or visitors know what special requirements are needed to ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2
... Now Approved with Four Indications for Five-Day Regimen, ... Food and Drug,Administration (FDA) has approved use of ... I.V. and oral, for the treatment of,complicated urinary ... This latest approval is based on results of ...
... The way the government keeps our,medicines ... goes through.,Those changes were the subject of ... Listen to this report from Pfizer at:, ... video, audio, text, graphics and,photos for free ...
... BKD ) announced today that its Board of ... stock of $0.50 per share for the,quarter ending September ... October 12, 2007 to holders of record of Brookdale,s ... Inc. is a leading owner and operator of senior,living ...
... VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Cardiome Pharma ... Chairman and Chief,Executive Officer, will present an overview ... in San Francisco at 8:00am Pacific Time,(11:00am Eastern ... live webcast of Mr. Rieder,s presentation can be ...
... Million People Nationwide to take 10 Billion, Steps and ... WASHINGTON, Sept. 17 More than 1,500 YMCAs nationwide,will ... living and,healthy eating during "America On the Move Week ... with the America On the Move,Foundation, aims to educate ...
... Company,s Executive Team, VIRGINIA BEACH, Va., Sept. ... announced that Mary McCluskey, MD, has been,named Chief ... 1.5 million members. "We are excited to ... AMERIGROUP President and Chief Executive Officer. "Throughout her,career, ...
Cached Medicine News:Health News:FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 2Health News:FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 3Health News:FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 4Health News:Cardiome to Present at ThinkEquity Conference 2Health News:Cardiome to Present at ThinkEquity Conference 3Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 2Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 3Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 4Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 5Health News:AMERIGROUP Names Mary McCluskey, MD, Chief Medical Officer 2Health News:AMERIGROUP Names Mary McCluskey, MD, Chief Medical Officer 3
... efficiency by reducing errors and eliminating costly ... solution, you can spend less time on ... more time on your patient care. Cardiology ... solution. With over 50,000 installations and a ...
... PrimeSuite, is a Web Browser-based Ambulatory ... Management, Electronic Medical Record (EMR) and ... the healthcare industrys demand for dependable ... of a suite of physician-centric software ...
... the Point-of Care Electronic Medical Record portion ... encounter documentation process and electronic patient record ... that is both mobile and secure. Using ... as pentop technology with a stylus device, ...
... EMR family of products offers complete ... of specialties. Intuition EMR enables physicians ... electronic record at the point of ... less time on documentation and more ...
Medicine Products: